Immunome (IMNM) stock price is $17.92, up 6.86% on the day, as of Oct 20, 2026. It has a market cap of $2.04Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap2.04 Bn
P/E-8.00
Div. Yield0.00
Add ratio to table…
About
Immunome Inc is a clinical-stage targeted oncology company focused on developing innovative therapies to improve outcomes for cancer patients. The company leverages its expertise in antibody-drug conjugates (ADCs), radioligand therapies, and small-molecule inhibitors to build a diversified pipeline of preclinical and clinical assets. Immunome’s strategy centers on identifying novel or underexplored biological targets to address unmet needs in oncology, with a particular…
Immunome Inc is a clinical-stage targeted oncology company focused on developing innovative therapies to improve outcomes for cancer patients. The company leverages its expertise in antibody-drug conjugates (ADCs), radioligand therapies, and small-molecule inhibitors to build a diversified pipeline of preclinical and clinical assets. Immunome’s strategy centers on identifying novel or underexplored biological targets to address unmet needs in oncology, with a particular emphasis on rare and aggressive tumor types. Its leadership team, which includes executives with prior roles in the successful development and commercialization of ADCs, drives the advancement of a robust portfolio designed to deliver first-in-class or best-in-class therapeutic options.
Immunome generates revenue through strategic partnerships, licensing agreements, and milestone payments tied to the development and commercialization of its product candidates. While the company has not yet commercialized any therapies, its business model relies on upfront payments, royalties, and potential future sales of approved products. Key revenue streams include payments from asset acquisitions, such as the $20 million cash and $50.6 million in equity issued to Ayala Pharmaceuticals for the varegacestat program, as well as milestone-based payments tied to regulatory and developmental achievements. Additionally, Immunome may secure funding through collaborations with larger pharmaceutical companies or government grants to support its research and clinical trials.
The company operates through the following segments:
Gamma Secretase Inhibitors: This segment focuses on varegacestat, an oral gamma secretase inhibitor currently in a Phase 3 clinical trial for the treatment of desmoid tumors. Varegacestat has demonstrated promising efficacy in earlier trials, with an objective response rate of 75% in evaluable patients and an 85% reduction in tumor cellularity. The program aims to address a rare but debilitating disease with limited treatment options, positioning varegacestat as a potential competitor to SpringWorks Therapeutics’ OGSIVEO.
Antibody-Drug Conjugates (ADCs): This segment encompasses a pipeline of ADCs targeting solid tumors and hematologic malignancies, including IM-1021, IM-1617, IM-1340, and IM-1335. IM-1021, a receptor tyrosine kinase-like orphan receptor 1 (ROR1) ADC, is in Phase 1 trials for solid tumors and B-cell lymphomas, leveraging Immunome’s proprietary HC74 topoisomerase 1 inhibitor payload. The ADC segment is designed to overcome challenges such as tumor heterogeneity and resistance mechanisms, with a focus on novel targets to differentiate from competitors like Merck and CStone Pharmaceuticals.
Radioligand Therapies: This segment includes IM-3050, a fibroblast activation protein (FAP)-targeted radioligand therapy for solid tumors. IM-3050 delivers radioactive lutetium-177 directly to FAP-expressing cells, leveraging a bystander effect to damage nearby tumor cells. The program aims to address limitations of existing FAP-targeted therapies, such as poor internalization, and competes with candidates from Novartis and Yantai LNC Biotechnology.
Immunome operates in the highly competitive oncology therapeutics market, where it competes with both specialized biotechnology firms and large pharmaceutical companies. Key competitors include ADC Therapeutics, Ipsen, Exelixis, Zymeworks, and Seagen (acquired by Pfizer), as well as radioligand therapy developers like RayzeBio (acquired by Bristol-Myers Squibb) and Fusion Pharmaceuticals (acquired by AstraZeneca). The company’s competitive advantages lie in its focus on underexplored biological targets, proprietary payload and linker technologies, and a leadership team with a proven track record in ADC development. Immunome’s strategy of pursuing novel targets, such as ROR1 and FAP, positions it to address gaps in the current treatment landscape, particularly for rare or aggressive cancers with limited therapeutic options.
Immunome’s customer base primarily consists of oncology patients with rare or aggressive tumor types, including desmoid tumors, B-cell lymphomas, and solid tumors such as non-small cell lung cancer, triple-negative breast cancer, and pancreatic cancer. The company’s therapies are designed to serve patients who have exhausted standard treatment options or lack effective alternatives. While Immunome does not yet have commercialized products, its future customer base will include hospitals, cancer treatment centers, and specialty pharmacies that administer oncology therapies. Additionally, the company may collaborate with diagnostic partners to develop companion diagnostics for patient selection, further refining its target market.
Sector:HealthcareSector rationaleImmunome is a clinical-stage oncology company developing pharmaceuticals such as antibody-drug conjugates (ADCs), radioligand therapies, and small-molecule inhibitors. Its revenue model is based on licensing agreements, milestone payments, and royalties typical of the biotechnology and pharmaceutical industries.Industries:BiotechnologyBiotechnologyPrimaryImmunome is a clinical-stage biotechnology company developing therapies derived from biological science, specifically antibody-drug conjugates (ADCs) like IM-1021 and radioligand therapies like IM-3050. Its revenue model is based on strategic partnerships, licensing agreements, and milestone payments typical of biotech developers.PharmaceuticalsPharmaceuticalsSecondaryThe company also develops small-molecule inhibitors, such as the oral gamma secretase inhibitor varegacestat, which falls under the development of branded prescription pharmaceuticals.Classified using BQ-MICSCIK: 0001472012
Bull & bear
Investment Thesis
▲ Bull case
Immunome's varegacestat has demonstrated exceptional efficacy in the Phase 3 RINGSIDE trial for desmoid tumors, achieving an 84% reduction in risk of disease progression or death (HR=0.16) versus placebo, with consistent benefit across key subgroups including tumor location, baseline tumor size, patient age, and prior therapy, indicating robust and generalizable results that support a strong likelihood of FDA approval following the NDA submission in April 2026, which could unlock a significant addressable market of approximately 1,000-1,650 new U.S. diagnoses annually and 10,000-11,000 actively managed patients, positioning varegacestat as a potential first-in-class standard of care with pricing power due to high unmet medical need and limited existing systemic therapies.
The RINGSIDE data revealed clinically meaningful patient-reported outcomes, including a statistically significant and rapid reduction in worst pain intensity (treatment difference of -2.42 points at week 12, p<0.0001), with improvement observed as early as week 4, which addresses a core burden of desmoid tumors not adequately captured by current therapies and enhances the product’s value proposition for both regulators and payers, potentially supporting favorable labeling, reimbursement, and rapid adoption upon approval, particularly given the chronic pain and quality-of-life impact driving disease burden in this patient population.
Beyond varegacestat, Immunome’s ADC pipeline shows tangible progress with IM-1021 demonstrating objective responses in B-cell lymphoma patients at multiple dose levels in ongoing Phase 1 trials, IM-1617 receiving IND clearance in April 2026, and plans to submit INDs for IM-1340 and IM-1335 in mid- and late-2026, respectively, all leveraging the proprietary HC74 TOP1 inhibitor payload that overcomes multi-drug resistance, creating near-term catalysts for additional clinical readouts and potential partnership interest that could diversify revenue streams and de-risk reliance on a single asset.
The company ended Q1 2026 with $582.7 million in cash and cash equivalents, providing a substantial cash runway to support varegacestat through potential FDA review, launch preparations, and continued ADC pipeline advancement without near-term dilution risk, as evidenced by the ability to fund operations while advancing multiple IND-enabling programs and preparing for commercial readiness, which reduces financing overhang and allows management to focus on execution rather than capital raising.
Structural shifts in the desmoid tumor treatment landscape favor Immunome’s approach, as current standards like surgery, radiation, and off-label systemic therapies (e.g., tyrosine kinase inhibitors) are limited by toxicity, recurrence, and lack of FDA approval, creating an opening for varegacestat as an oral, once-daily targeted therapy with a manageable safety profile (mostly Grade 1/2 adverse events) and demonstrated tumor shrinkage (-83% median best change vs. +11% placebo), which could capture significant market share rapidly if approved, especially given the absence of direct competitors in late-stage development for this indication.
Immunome's varegacestat has demonstrated exceptional efficacy in the Phase 3 RINGSIDE trial for desmoid tumors, achieving an 84% reduction in risk of disease progression or death (HR=0.16) versus placebo, with consistent benefit across key subgroups including tumor location, baseline tumor size, patient age, and prior therapy, indicating robust and generalizable results that support a strong likelihood of FDA approval following the NDA submission in April 2026, which could unlock a significant addressable market of approximately 1,000-1,650 new U.S. diagnoses annually and 10,000-11,000 actively managed patients, positioning varegacestat as a potential first-in-class standard of care with pricing power due to high unmet medical need and limited existing systemic therapies.
The RINGSIDE data revealed clinically meaningful patient-reported outcomes, including a statistically significant and rapid reduction in worst pain intensity (treatment difference of -2.42 points at week 12, p<0.0001), with improvement observed as early as week 4, which addresses a core burden of desmoid tumors not adequately captured by current therapies and enhances the product’s value proposition for both regulators and payers, potentially supporting favorable labeling, reimbursement, and rapid adoption upon approval, particularly given the chronic pain and quality-of-life impact driving disease burden in this patient population.
Beyond varegacestat, Immunome’s ADC pipeline shows tangible progress with IM-1021 demonstrating objective responses in B-cell lymphoma patients at multiple dose levels in ongoing Phase 1 trials, IM-1617 receiving IND clearance in April 2026, and plans to submit INDs for IM-1340 and IM-1335 in mid- and late-2026, respectively, all leveraging the proprietary HC74 TOP1 inhibitor payload that overcomes multi-drug resistance, creating near-term catalysts for additional clinical readouts and potential partnership interest that could diversify revenue streams and de-risk reliance on a single asset.
The company ended Q1 2026 with $582.7 million in cash and cash equivalents, providing a substantial cash runway to support varegacestat through potential FDA review, launch preparations, and continued ADC pipeline advancement without near-term dilution risk, as evidenced by the ability to fund operations while advancing multiple IND-enabling programs and preparing for commercial readiness, which reduces financing overhang and allows management to focus on execution rather than capital raising.
Structural shifts in the desmoid tumor treatment landscape favor Immunome’s approach, as current standards like surgery, radiation, and off-label systemic therapies (e.g., tyrosine kinase inhibitors) are limited by toxicity, recurrence, and lack of FDA approval, creating an opening for varegacestat as an oral, once-daily targeted therapy with a manageable safety profile (mostly Grade 1/2 adverse events) and demonstrated tumor shrinkage (-83% median best change vs. +11% placebo), which could capture significant market share rapidly if approved, especially given the absence of direct competitors in late-stage development for this indication.
Despite the compelling efficacy data, varegacestat’s safety profile presents significant tolerability challenges, with 80% of patients requiring dose reductions due to treatment-emergent adverse events versus 9% on placebo, and 20% discontinuing treatment due to adverse events versus 7% on placebo, which raises concerns about real-world adherence and long-term usability, particularly given the chronic nature of desmoid tumor management and the high prevalence of gastrointestinal (diarrhea 82%), dermatologic (rash 43%), and fatigue-related (44%) events that could diminish quality-of-life benefits and limit uptake even if approved.
Ovarian toxicity emerged as a notable risk in premenopausal women, with 56% (20 of 36) experiencing adverse events, and while most resolved, the lack of full reversibility in 45% of affected patients and potential long-term fertility implications could trigger restrictive labeling, pregnancy testing requirements, or contraindications that severely limit the addressable patient pool, especially since desmoid tumors disproportionately affect women and often present during reproductive years, undermining the commercial potential of an otherwise effective therapy.
The NDA submission for varegacestat in April 2026 relies entirely on the RINGSIDE trial, and while the primary and secondary endpoints were met, there is no mention of overall survival (OS) data or long-term durability of response beyond the trial’s follow-up period, leaving open the risk that the FDA may question the sufficiency of progression-free survival and response rate as a basis for approval without OS benefit, particularly given that desmoid tumors are non-metastatic and indolent in nature, which could lead to a complete response letter, advisory committee review, or request for additional data, delaying launch and increasing costs.
Immunome’s financials reveal a growing accumulated deficit of $782.0 million as of March 31, 2026, up from $728.2 million at December 31, 2025, reflecting continued heavy investment in R&D ($177.3 million in 2025) and G&A ($43.8 million), with collaboration revenue declining to zero in Q1 2026 from $2.9 million in the prior year period, indicating no near-term offsetting income from partnerships and increasing reliance on cash reserves to fund operations, which could pressure the balance sheet if varegacestat faces regulatory delays or if ADC programs fail to meet early milestones, potentially necessitating dilutive financing sooner than anticipated.
The desmoid tumor market, while underserved, remains small and niche, with only 1,000-1,650 new U.S. cases annually and a prevalence of 10,000-11,000 actively managed patients, which limits peak sales potential even under optimistic capture scenarios, and without clear pricing benchmarks or comparator therapies, there is significant uncertainty around achievable net prices, rebates, and payer acceptance, especially if cost-effectiveness analyses are unfavorable due to the chronic dosing requirement and management of adverse events, potentially constraining revenue upside below levels needed to justify current valuations or support pipeline expansion.
Despite the compelling efficacy data, varegacestat’s safety profile presents significant tolerability challenges, with 80% of patients requiring dose reductions due to treatment-emergent adverse events versus 9% on placebo, and 20% discontinuing treatment due to adverse events versus 7% on placebo, which raises concerns about real-world adherence and long-term usability, particularly given the chronic nature of desmoid tumor management and the high prevalence of gastrointestinal (diarrhea 82%), dermatologic (rash 43%), and fatigue-related (44%) events that could diminish quality-of-life benefits and limit uptake even if approved.
Ovarian toxicity emerged as a notable risk in premenopausal women, with 56% (20 of 36) experiencing adverse events, and while most resolved, the lack of full reversibility in 45% of affected patients and potential long-term fertility implications could trigger restrictive labeling, pregnancy testing requirements, or contraindications that severely limit the addressable patient pool, especially since desmoid tumors disproportionately affect women and often present during reproductive years, undermining the commercial potential of an otherwise effective therapy.
The NDA submission for varegacestat in April 2026 relies entirely on the RINGSIDE trial, and while the primary and secondary endpoints were met, there is no mention of overall survival (OS) data or long-term durability of response beyond the trial’s follow-up period, leaving open the risk that the FDA may question the sufficiency of progression-free survival and response rate as a basis for approval without OS benefit, particularly given that desmoid tumors are non-metastatic and indolent in nature, which could lead to a complete response letter, advisory committee review, or request for additional data, delaying launch and increasing costs.
Immunome’s financials reveal a growing accumulated deficit of $782.0 million as of March 31, 2026, up from $728.2 million at December 31, 2025, reflecting continued heavy investment in R&D ($177.3 million in 2025) and G&A ($43.8 million), with collaboration revenue declining to zero in Q1 2026 from $2.9 million in the prior year period, indicating no near-term offsetting income from partnerships and increasing reliance on cash reserves to fund operations, which could pressure the balance sheet if varegacestat faces regulatory delays or if ADC programs fail to meet early milestones, potentially necessitating dilutive financing sooner than anticipated.
The desmoid tumor market, while underserved, remains small and niche, with only 1,000-1,650 new U.S. cases annually and a prevalence of 10,000-11,000 actively managed patients, which limits peak sales potential even under optimistic capture scenarios, and without clear pricing benchmarks or comparator therapies, there is significant uncertainty around achievable net prices, rebates, and payer acceptance, especially if cost-effectiveness analyses are unfavorable due to the chronic dosing requirement and management of adverse events, potentially constraining revenue upside below levels needed to justify current valuations or support pipeline expansion.